PTC Therapeutics
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $357,807 | $360,519 | $272,551 | $164,677 |
Gross Profit | 334,143 | 340,598 | 244,523 | 148,378 |
EBITDA | 21,595 | 161,900 | 61,981 | -70,993 |
EBIT | 4,778 | 146,026 | 46,568 | -83,895 |
Net Income | -51,693 | 83,496 | -2,809 | -134,965 |
Net Change In Cash | 357,807 | 360,519 | 272,551 | 164,677 |
Free Cash Flow | -27,968 | 121,969 | -60,395 | -71,564 |
Cash | 508,894 | 1,049,887 | 833,986 | 984,648 |
Basic Shares | 83,476 | 92,020 | 82,521 | 80,689 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $1,730,655 | $806,780 | $937,822 | $698,801 |
Gross Profit | 1,658,900 | 749,382 | 872,336 | 654,123 |
EBITDA | 887,664 | -120,463 | -330,340 | -367,780 |
EBIT | 848,849 | -196,126 | -566,930 | -496,616 |
Net Income | 682,644 | -363,295 | -626,604 | -559,017 |
Net Change In Cash | 1,730,655 | 806,780 | 937,822 | 698,801 |
Cost of Revenue | 101,479 | |||
Free Cash Flow | 411,184 | -181,937 | -279,037 | -509,114 |
Cash | 984,648 | 779,709 | 594,001 | 279,834 |
Basic Shares | 88,311 | 76,845 | 74,838 | 71,728 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | $0.61 |
2026-06-30 | $0.92 |
2026-03-31 | -$0.03 |
2025-12-31 | -$1.80 |